Ligand Pharmaceuticals Incorporated · NASDAQ:LGND

Reardon Andrew sold 5,000 Ligand Pharmaceuticals Incorporated shares (Form 4)

Traded Aug 3, 2026 · Filed Aug 4, 2026

On Aug 3, 2026, Reardon Andrew (CLO & Secretary) sold 5,000 Ligand Pharmaceuticals Incorporated shares at an average US$288.99 for US$1.44M under a trading plan, leaving 41,514 shares. Filed Aug 4, 2026 (Form 4).

Sold
5,000 shares
Price
US$288.99 average (US$284.14 to US$292.82)
Value
US$1.44M
Holding after
41,514 shares
Trading plan
Yes (Made under a plan set in advance)
Role
CLO & Secretary

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Aug 3, 2026Common StockOption exercise5,000US$52.2746,514Direct
Aug 3, 2026Common StockSale105US$284.1446,409Direct
Aug 3, 2026Common StockSale33US$284.5546,376Direct
Aug 3, 2026Common StockSale157US$285.7446,219Direct
Aug 3, 2026Common StockSale1,032US$286.8045,187Direct
Aug 3, 2026Common StockSale1,214US$287.7743,973Direct
Aug 3, 2026Common StockSale356US$288.7543,617Direct
Aug 3, 2026Common StockSale503US$289.8043,114Direct
Aug 3, 2026Common StockSale200US$290.6042,914Direct
Aug 3, 2026Common StockSale991US$291.7141,923Direct
Aug 3, 2026Common StockSale409US$292.8241,514Direct

Source

View original at SEC

Related